• Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Eris Share Price

    Eris Lifesciences Share PriceEris Lifesciences

    Mid Cap 6.9k Result
    ₹876.35
    -24.2 (-2.69%)
    • Advice
    • Hold
    As on 11 December, 2023 | 02:38 BSE: 540596 NSE: ERISISIN: INE406M01024

    Eris Lifesciences Performance

    Day Range

    • Low 872.35
    • High 905.00
    ₹ 876.35

    52 Week Range

    • Low 551.30
    • High 971.90
    ₹ 876.35
    • Open Price905.00
    • Previous Close900.55
    • Volume78788

    Start SIP in Eris Lifesciences

    Start SIP

    Eris Lifesciences Share Price

    • Over 1 Month -2.39%
    • Over 3 Month 6.1%
    • Over 6 Month 35.36%
    • Over 1 Year 32.75%

    Eris Lifesciences Key Statistics

    P/E Ratio 30.9
    PEG Ratio -12.9
    Market Cap Cr 11,920
    Price to Book Ratio 5.4
    EPS 28.9
    Dividend 0
    Relative Strength Index 40.78
    Money Flow Index 46.36
    MACD Signal 13.07
    Average True Range 27.54

    Eris Lifesciences Investment Rating

    • Master Rating:

    • Eris Lifesciences has an operating revenue of Rs. 1,797.98 Cr. on a trailing 12-month basis. An annual revenue growth of 24% is outstanding, Pre-tax margin of 24% is great, ROE of 17% is exceptional. The company has a reasonable debt to equity of 29%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 50DMA and around 18% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart and is trading around -5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 58 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 117 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Eris Lifesciences Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 410411308327350322277
    Operating Expenses Qtr Cr 265256203206214203181
    Operating Profit Qtr Cr 144156111126141126102
    Depreciation Qtr Cr 25201716161515
    Interest Qtr Cr 7733771
    Tax Qtr Cr 2228119128
    Net Profit Qtr Cr 11811188991159687
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,3481,245
    Operating Expenses Annual Cr 826732
    Operating Profit Annual in Cr 505484
    Depreciation Cr 6551
    Interest Annual Cr 213
    Tax Annual Cr 3941
    Net Profit Annual Cr 398417
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 322369
    Cash from Investing Activity Annual Cr -513-268
    Cash from Financing Annual Activity Cr 194-88
    Net Cash Flow Annual Cr 313
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 2,2221,918
    Fixed Assets Annual Cr 898645
    Total Non Current Assets Annual Cr 2,2321,570
    Total Current Assets Annual Cr 552580
    Total Assets Annual Cr 2,7842,150
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 163141
    ROE Annual % 1822
    ROCE Annual % 1823
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3942
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 505467397418455392301
    Operating Expenses Qtr Cr 324297284286309269209
    Operating Profit Qtr Cr 18117011913715112997
    Depreciation Qtr Cr 42413530292318
    Interest Qtr Cr 161793771
    Tax Qtr Cr 419146285
    Net Profit Qtr Cr 12395651021199580
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 1,6961,373
    Operating Expenses Annual Cr 1,148862
    Operating Profit Annual in Cr 537485
    Depreciation Cr 11765
    Interest Annual Cr 264
    Tax Annual Cr 3036
    Net Profit Annual Cr 382406
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 292378
    Cash from Investing Activity Annual Cr -982-320
    Cash from Financing Annual Activity Cr 688-45
    Net Cash Flow Annual Cr -214
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 2,1961,908
    Fixed Assets Annual Cr 2,258851
    Total Non Current Assets Annual Cr 2,9031,645
    Total Current Assets Annual Cr 765627
    Total Assets Annual Cr 3,6672,272
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 163140
    ROE Annual % 1721
    ROCE Annual % 1322
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 3338
    Invest in Eris Lifesciences

    Eris Lifesciences Technicals

    EMA & SMA

    Current Price
    ₹876.35
    -24.2 (-2.69%)
    pointer
    • Bullish Moving Average
    • ___
    • 5
    • Bearish Moving Average
    • ___
    • 11
    • 20 Day
    • ₹910.31
    • 50 Day
    • ₹886.47
    • 100 Day
    • ₹842.47
    • 200 Day
    • ₹784.11
    • 20 Day
    • ₹919.72
    • 50 Day
    • ₹890.22
    • 100 Day
    • ₹846.75
    • 200 Day
    • ₹739.74

    Eris Lifesciences Resistance and Support

    PIVOT
    ₹884.57
    Resistance
    First Resistance 896.78
    Second Resistance 917.22
    Third Resistance 929.43
    RSI 40.78
    MFI 46.36
    MACD Single Line 13.07
    MACD 5.59
    Support
    First Resistance 864.13
    Second Resistance 851.92
    Third Resistance 831.48

    Eris Lifesciences Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 81,592 4,588,734 56.24
    Week 74,865 4,356,371 58.19
    1 Month 163,674 5,918,457 36.16
    6 Month 190,721 10,754,785 56.39

    Eris Lifesciences Result Highlights

    Eris Lifesciences Synopsis

    NSE-Medical-Biomed/Biotech

    Eris Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1330.73 Cr. and Equity Capital is Rs. 13.60 Cr. for the Year ended 31/03/2023. Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867.
    Market Cap 11,920
    Sales 1,468
    Shares in Float 6.12
    No of funds 117
    Yield
    Book Value 5.36
    U/D Vol ratio 2
    LTDebt / Equity 9
    Alpha 0.09
    Beta 0.44

    Eris Lifesciences

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 54.91%52.86%52.86%52.7%
    Mutual Funds 13.86%10.27%9.64%9.64%
    Insurance Companies 0.01%
    Foreign Portfolio Investors 13.2%13.78%14.86%15.5%
    Financial Institutions/ Banks
    Individual Investors 15.47%22.07%21.66%21.45%
    Others 2.56%1.01%0.98%0.71%

    Eris Lifesciences Management

    Name Designation
    Mr. Amit Bakshi Chairperson & Managing Director
    Mr. Krishnakumar Vaidyanathan COO & Executive Director
    Mr. Inderjeet Singh Negi Executive Director
    Mr. Kaushal Shah Executive Director
    Mr. Rajeev Dalal Independent Director
    Mr. Vasudevan Sujesh Independent Director
    Ms. Kalpana Unadkat Independent Director
    Mr. Prashant Gupta Independent Director

    Eris Lifesciences Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Eris Lifesciences Corporate Action

    Date Purpose Remarks
    2023-11-08 Quarterly Results
    2023-08-07 Quarterly Results
    2023-05-17 Audited Results
    2023-01-17 Quarterly Results
    2022-10-20 Quarterly Results
    Date Purpose Remarks
    2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
    2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend

    Eris Lifesciences MF Shareholding

    Name Amount(cr)
    HDFC Small Cap Fund Growth 25,409
    UTI Flexi Cap Fund Regular Plan Growth 24,370
    HDFC Large and Mid Cap Fund Growth 13,428
    Franklin India Smaller Companies Fund Growth 10,777
    HDFC Multi Cap Fund Regular Growth 10,000

    Eris Lifesciences FAQs

    What is Share Price of Eris Lifesciences ?

    Eris Lifesciences share price is ₹876 As on 11 December, 2023 | 02:24

    What is the Market Cap of Eris Lifesciences ?

    The Market Cap of Eris Lifesciences is ₹11920.4 Cr As on 11 December, 2023 | 02:24

    What is the P/E ratio of Eris Lifesciences ?

    The P/E ratio of Eris Lifesciences is 30.9 As on 11 December, 2023 | 02:24

    What is the PB ratio of Eris Lifesciences ?

    The PB ratio of Eris Lifesciences is 5.4 As on 11 December, 2023 | 02:24

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.